🔴 Summit Therapeutics is trading 5% down

Summit Therapeutics is trading 5.07% lower at $15.28 on November 5, 2026; available information does not establish a specific cause for the decline.

• Third-quarter loss per share was narrower than consensus, and the company reported a $2 billion AstraZeneca investment.
• The FDA’s November 14 decision on ivonescimab remains a near-term uncertainty.
• Broader U.S. indexes were lower while the biotech sector was up; the evidence does not clearly attribute the move to either trend. No trading volume information was provided.